Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with ...

Novo Nordisk considers exploring GLP-1 drugs like semaglutide for addiction treatment, following Eli Lilly's interest.

Despite comments made by a Novo Nordisk official this week, the company confirmed to BioSpace that it has no additional ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy at half its price, amounting to $499 per month.

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 ...

COPENHAGEN, March 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...

Danish obesity drug giant looking at whether its semaglutide drug can reduce cravings associated with addiction ...